Directorate Change

RNS Number : 8383C

Hikma Pharmaceuticals Plc

13 October 2022

 

Hikma appoints Deneen Vojta, M.D. as a Director

London, 13 October 2022 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) ( Hikma ) announces the appointment of Deneen Vojta, M.D. as an independent Non-Executive Director, effective 1 November 2022.

Commenting on the appointment, Said Darwazah, Executive Chairman and CEO said 'I am delighted to welcome Deneen to the Hikma Board, 'Deneen is a seasoned healthcare executive and medical professional with extensive experience working in large, international, high growth organisations across the entire spectrum of the healthcare system. She brings to the Board experience as both an entrepreneur and a strategic leader in the healthcare industry.'

Deneen is President of Health Solutions and Innovation at Turning Point Healthcare Solutions, a provider of specialty case management services and technologies. Prior to this, she was Executive Vice President for Research and Development at UnitedHealth Group (UHG), where she was responsible for building new businesses and creating innovative payment and delivery system frameworks. She was also the Founder and CEO of MYnetico, a digital weight management platform acquired by UHG in 2006. Earlier, she served as Chief Medical O ff icer of ARIA Health Care System and Health Partners of Philadelphia.

Deneen is currently a Non-Executive Director of Sensei Biotherapeutics, Workit Health and Children's Minnesota.

-- ENDS --

Enquiries:

Hikma Pharmaceuticals PLC

Hussein Arkhagha, Chief Counsel and Company Secretary                         [phone]

Susan Ringdal, EVP Strategic Planning and Global Affairs      [phone]

 

END

 

 

BOAGPGBUUUPPGWW